Design of monitoring system for radioactivity and radiation dose in nuclear medicine

In this paper, an intelligent radioactivity and radiation dose monitoring system is designed, which can be used in the field of nuclear medicine. The system can dynamically monitor the body surface radioactivity and radiation dose rate of patients receiving 131I radioactive drug treatment, and can identify the personnel who exceed the radiation threshold and send out sound and light alarm. Compared with other monitoring equipment, this system has higher accuracy and can guide the clinical treatment of nuclear medicine scientifically.

Use of 55 PET radiotracers under approval of a Radioactive Drug Research Committee (RDRC)

Background In the US, EU and elsewhere, basic clinical research studies with positron emission tomography (PET) radiotracers that are generally recognized as safe and effective (GRASE) can often be conducted under institutional approval. For example, in the United States, such research is conducted under the oversight of a Radioactive Drug Research Committee (RDRC) as long as certain requirements are met. Firstly, the research must be for basic science and cannot be intended for immediate therapeutic or diagnostic purposes, or to determine the safety and effectiveness of the PET radiotracer. Secondly, the PET radiotracer must be generally recognized as safe and effective. Specifically, the mass dose to be administered must not cause any clinically detectable pharmacological effect in humans, and the radiation dose to be administered must be the smallest dose practical to perform the study and not exceed regulatory dose limits within a 1-year period. In our experience, the main barrier to using a PET radiotracer under RDRC approval is accessing the required information about mass and radioactive dosing. Results The University of Michigan (UM) has a long history of using PET radiotracers in clinical research studies. Herein we provide dosing information for 55 radiotracers that will enable other PET Centers to use them under the approval of their own RDRC committees. Conclusions The data provided herein will streamline future RDRC approval, and facilitate further basic science investigation of 55 PET radiotracers that target functionally relevant biomarkers in high impact disease states.

BMS-599626, a Highly Selective Pan-HER Kinase Inhibitor, Antagonizes ABCG2-Mediated Drug Resistance

Multidrug resistance (MDR) associated with the overexpression of ABC transporters is one of the key causes of chemotherapy failure. Various compounds blocking the function and/or downregulating the expression of these transporters have been developed over the last few decades. However, their potency and toxicity have always been a concern. In this report, we found that BMS-599626 is a highly potent inhibitor of the ABCG2 transporter, inhibiting its efflux function at 300 nM. Our study repositioned BMS-599626, a highly selective pan-HER kinase inhibitor, as a chemosensitizer in ABCG2-overexpressing cell lines. As shown by the cytotoxicity assay results, BMS-599626, at noncytotoxic concentrations, sensitizes ABCG2-overexpressing cells to topotecan and mitoxantrone, two well-known substrates of ABCG2. The results of our radioactive drug accumulation experiment show that the ABCG2-overexpressing cells, treated with BMS-599626, had an increase in the accumulation of substrate chemotherapeutic drugs, as compared to their parental subline cells. Moreover, BMS-599626 did not change the protein expression or cell surface localization of ABCG2 and inhibited its ATPase activity. Our in-silico docking study also supports the interaction of BMS-599626 with the substrate-binding site of ABCG2. Taken together, these results suggest that administration of chemotherapeutic drugs, along with nanomolar concentrations (300 nM) of BMS-599626, may be effective against ABCG2-mediated MDR in clinical settings.

Inhibition of protohaem ferro-lyase in experimental porphyria. Isolation and partial characterization of a modified porphyrin inhibitor

1. A modified porphyrin with inhibitory activity towards protohaem ferro-lyase was purified from the livers of mice treated with 3,5-diethoxycarbonyl-1,4-dihydrocollidine, and partially characterized. 2. The inhibitor can be labelled by 5-amino[4-14C]-laevulinate, suggesting that it originates from pre-labelled liver haem. No radioactivity from 3,5-diethoxycarbonyl-1,4-dihydro[2,6-14C]collidine can be recovered bound to the purified abnormal porphyrin when the radioactive drug is used to induce its formation. 3. Similar modified porphyrins isolated from the livers of animals treated with 2-allyl-2-isopropylacetamide, secobarbitone or 1-ethynylcyclohexanol did not exhibit inhibitory activity toward protohaem ferro-lyase. 4. The inhibition of protohaem ferro-lyase was progressive, could be slowed down by cooling and partially prevented by preincubating the enzyme with the porphyrin substrate. Once established, inhibition could not be reversed by addition of the substrate 5. These results suggest that the modified porphyrin irreversibly inhibits protohaem ferro-lyase and may be used as a sensitive and selective reagent to titrate the number of active centres of the enzyme.